Cargando…

Large-scale production of lentiviral vectors using multilayer cell factories

Lentiviral-mediated gene therapy has been proposed for the treatment of a range of diseases, and due to its genome integration properties, it offers the potential for long-lasting benefit from a once-off treatment. Production methods for pre-clinical studies in animal models, and ultimately for huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Rout-Pitt, Nathan, McCarron, Alexandra, McIntyre, Chantelle, Parsons, David, Donnelley, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Biological Methods 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706103/
https://www.ncbi.nlm.nih.gov/pubmed/31453241
http://dx.doi.org/10.14440/jbm.2018.236
Descripción
Sumario:Lentiviral-mediated gene therapy has been proposed for the treatment of a range of diseases, and due to its genome integration properties, it offers the potential for long-lasting benefit from a once-off treatment. Production methods for pre-clinical studies in animal models, and ultimately for human clinical trials, must be capable of producing large quantities of high-quality lentiviral vector in an efficient and cost-effective manner. We report here a medium-scale method (from 1.5 L to 6 L of vector supernatant) for lentiviral vector production in adherent cell cultures using the NUNC™ EasyFill™ Cell Factory™ from Thermo Fisher Scientific. Downstream purification uses a Mustang Q XT5 anion exchange capsule from Pall, and an ultracentrifugation step to concentrate the vector. This method is capable of producing lentiviral vector with concentrated titres of 10(8)–10(9) TU/ml, with reduced manual handling compared to single monolayer flask methods.